PDCD1LG2 and neoplasm: Furthermore, we found that LAMP3+ DCs exhibit the regulation activity towards B cells, Tregs, CD4+ and CD8+ T lymphocytes through PD1/PD-L1 and PD1/PD-L2 signaling pathways, as well as NK/NKT cells via CD226/NECTIN2 and TIGIT/NECTIN2 pathways, and macrophage and DCs cells via CD80 interacted with PD-L1 to disrupt PD-L1/PD-1 binding to promote anti-tumor T cell response [36] (Fig. 6F, Supplementary Figs. S5, S6).